The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase
Abstract
Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor-bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intriguingly, both ASS1 and ASL enzymes are frequently epigenetically silenced in melanoma, renal cell carcinoma and hepatocellular carcinoma (Bowles et al., 2008; Ensor et al., 2002; Yoon et al., 2007).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yoon et al., 2007
Citations
Cites
Multiple Comparisons Using Rank Sums
Dunn, O. J. (1964) · Technometrics · doi:10.1080/00401706.1964.10490181 · Cited by 5,168
Papapetropoulos, A., García‐Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,195
Protein A, avidin, and biotin in immunohistochemistry.
Hsu, S. M., & Raine, L. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.11.6172466 · Cited by 638
Enzymes of Arginine Metabolism
Morris, S. M. (2004) · Journal of Nutrition · doi:10.1093/jn/134.10.2743s · Cited by 361
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2004) · Cancer · doi:10.1002/cncr.20057 · Cited by 317
Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315
Sasaki, K., Hattori, T., Fujisawa, T., Takahashi, K., Inoue, H., & Takigawa, M. (1998) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021955 · Cited by 272
Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.120 · Cited by 250
Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0933 · Cited by 238
Relative importance of kidney and liver in synthesis of arginine by the rat
Featherston, W. R., Rogers, Q. R., & Freedland, R. (1973) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1973.224.1.127 · Cited by 186
Cited by
Sorted by citations
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Metabolic reprogramming in clear cell renal cell carcinoma
Wettersten, H. I., Aboud, O. A., Lara, P. N., & Weiss, R. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.59 · Cited by 587
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
Delage, B., Fennell, D. A., Nicholson, L., McNeish, I., Lemoine, N. R., Crook, T., & Szlosarek, P. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25202 · Cited by 441
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 446
Kim, R. H., Coates, J. M., Bowles, T. L., McNerney, G. P., Sutcliffe-Goulden, J., Jung, J. U., Gandour‐Edwards, R. F., Chuang, F. Y. S., Bold, R. J., & Kung, H.-J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3157 · Cited by 321
Metadata
- Authors
- Yoon, C., Shim, Y., Kim, E., Lee, J., Won, N., Kim, J., Park, I., Yoon, D., & Min, B.
- Affiliations
- Korea University (KR)
- Seoul National University (KR)
- Inha University (KR)
- Corresponding author
- Min, Bon‐Hong
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2006-12-27
- Volume
- 120
- Issue
- 4
- Pages
- 897-905
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1983116683
- Cited by
- 165
- References
- 37
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 9 · 2018: 9 · 2017: 11 · 2016: 8 · 2015: 7 · 2014: 10 · 2013: 8 · 2012: 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A050252)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- renal cell carcinoma, argininosuccinate synthetase, arginine deiminase, arginine deprivation, tumor growth inhibition, tumor angiogenesis, vascular endothelial growth factor, neovascularization, proximal tubule, Renca cells, cancer therapy
- MeSH terms
- Adult, Aged, Animals, Arginase, Arginine, Argininosuccinate Synthase, Carcinoma, Renal Cell, Citrulline, Female, Humans, Hydrolases, Kidney Neoplasms, Male, Mice, Inbred BALB C, Middle Aged, Neovascularization, Pathologic, Polyethylene Glycols, Tumor Cells, Cultured, Survival Rate, Xenograft Model Antitumor Assays, Vascular Endothelial Growth Factor A, Cell Growth Processes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
